{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:44:27Z","timestamp":1793198667006,"version":"4.5.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015286","name":"Hebei Provincial Key Research Projects","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015286","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015285","name":"Hebei Province Medical Science Research Key Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015285","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Chemotherapy-induced peripheral neuropathy (CIPN) is a common and severe adverse reaction in taxane-based chemotherapy. This study aimed to analyze the risk factors of peripheral neuropathy in patients with breast cancer receiving paclitaxel chemotherapy to provide a reference for the early prevention of CIPN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included 350 patients with breast cancer who received chemotherapy for the first time at the Tangshan People\u2019s Hospital between August 2022 and June 2023 and were followed for at least 3 months after the end of chemotherapy. The incidence of CIPN in patients with breast cancer was calculated, and risk factors for CIPN were analyzed using logistic regression analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The incidence rate of CIPN was 79.1%. Multifactor logistic regression analysis indicated that age \u226545 years [odds ratio (OR)=5.119, 95% confidence interval (CI)=1.395\u201318.780] and \u226560 years (OR=9.366, 95% CI=1.228\u201371.421), history of hypertension (OR=3.475, 95% CI=1.073\u201311.250), cumulative dose of chemotherapy drugs &amp;gt;900 mg (OR=4.842, 95% CI=1.961\u20135.946), vitamin D deficiency (OR=6.214, 95% CI=2.308\u201316.729), abnormal alanine aminotransferase (OR=3.154, 95% CI=1.010\u20139.844), anemia before chemotherapy (OR=2.770, 95% CI=1.093\u20137.019), infusion duration of chemotherapy drugs &amp;gt;30\u00a0min (OR=3.673, 95% CI=1.414\u20139.539), body mass index \u226524 kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      (OR=8.139, 95% CI=1.157\u201357.240), mild depression (OR=4.546, 95% CI=1.358\u201315.223), and major depression (OR=4.455, 95% CI=1.237\u201316.037) increased the risk of CIPN. Having a regular caregiver (OR=0.223, 95% CI=0.087\u20130.573), high levels of physical activity (OR=0.071, 95% CI=0.008\u20130.647), and strong social support (OR=0.048, 95% CI=0.003\u20130.682) were protective factors against CIPN.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Clinical attention should be paid to patients with these risk factors, and active and effective preventive measures should be taken to reduce the occurrence of CIPN and improve the quality of life.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2024.1327318","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T07:21:51Z","timestamp":1709796111000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":43,"title":["Risk factors of paclitaxel-induced peripheral neuropathy in patients with breast cancer: a prospective cohort study"],"prefix":"10.3389","volume":"14","author":[{"given":"Sun","family":"Lixian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xiaoqian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo","family":"Luyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Lizhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Du","family":"Rui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Hongyue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Caijie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Fenghui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3322\/caac.21204","article-title":"Chemotherapy-induced peripheral neurotoxicity: a critical analysis","volume":"63","author":"Park","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.11.011","article-title":"Chemotherapy-induced peripheral neuropathy: Current status and progress","volume":"140","author":"Brewer","year":"2016","journal-title":"Gynecol Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"102831","DOI":"10.1016\/j.critrevonc.2019.102831","article-title":"Prevention of chemotherapy-induced peripheral neuropathy: A review of recent findings","volume":"145","author":"Ibrahim","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24951","article-title":"Chemotherapy-induced peripheral neuropathy: A current review","volume":"81","author":"Staff","year":"2017","journal-title":"Ann Neurol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2014.04.004","article-title":"Chemotherapy-induced neuropathy: A comprehensive survey","volume":"40","author":"Miltenburg","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/NJH.0000000000000240","article-title":"Symptom clusters in Korean patients with metastatic cancer undergoing palliative chemotherapy","volume":"18","author":"Kim","year":"2016","journal-title":"J Hospice Palliative Nurs"},{"key":"B7","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1634\/theoncologist.2018-0298","article-title":"Age and the risk of paclitaxel-induced neuropathy in women with early-stage breast cancer (Alliance A151411): Results from 1,881 patients from cancer and leukemia group B (CALGB) 40101","volume":"24","author":"Barginear","year":"2019","journal-title":"Oncologist"},{"key":"B8","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1186\/s12885-018-4869-5","article-title":"Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer","volume":"18","author":"Ghoreishi","year":"2018","journal-title":"BMC Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.04.023","article-title":"Identification of high-risk drugs related to chemotherapy-induced peripheral neuropathy in Cancer Therapy Evaluation Program\u2013 sponsored phase I trials","volume":"1","author":"Kishimoto","year":"2019","journal-title":"Eur J Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0418","article-title":"Concomitant medications and risk of chemotherapy-induced peripheral neuropathy","volume":"24","author":"S\u00e1nchez-Barroso","year":"2019","journal-title":"Oncologist"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4328","article-title":"Chemotherapy-induced peripheral neuropathy in African American cancer survivors: Risk factors and quality of life outcomes","volume":"10","author":"Trendowski","year":"2021","journal-title":"Cancer Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.7314\/APJCP.2015.16.17.7603","article-title":"Prevalence of oxaliplatin-induced chronic neuropathy and influencing factors in patients with colorectal cancer in Iran","volume":"16","author":"Shahriari-Ahmadi","year":"2015","journal-title":"Asian Pacific J Cancer Prev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-07093-4","article-title":"Anxiety symptoms but not depression symptoms before taxane chemotherapy initiation are associated with peripheral neuropathy: a multicenter study in women with breast cancer","volume":"30","author":"Verhoeff-Jahja","year":"2022","journal-title":"Supporting Cancer Care August"},{"key":"B14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s10826-016-0535-1","article-title":"Psychometric properties of the perceived social support from family and friends scale: Data from an adolescent sample in Ghana","volume":"26","author":"Glozah","year":"2017","journal-title":"J Child Family Stud"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13000","article-title":"Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT\/GOG-Ntx)","volume":"15","author":"Cheng","year":"2019","journal-title":"Asia Pac J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1671-8348.2014.03.002","article-title":"Reliability and validity of Pittsburgh sleep Quality index","volume":"43","author":"Lu","year":"2014","journal-title":"Chongqing Med"},{"key":"B17","first-page":"42","article-title":"Social support rating scale","volume":"7","author":"Xiao","year":"1993","journal-title":"Chin J Ment Health"},{"key":"B18","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/1471-2466-14-158","article-title":"Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease-a randomized, multicenter, double-blind, placebo-controlled study","volume":"14","author":"Watz","year":"2014","journal-title":"BMC Pulm Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/tbj.14123","article-title":"Persistent taxan-induced neuropathy in elderly patients treated for localized breast cancer","volume":"26","author":"Pabst","year":"2020","journal-title":"Breast Journal December"},{"key":"B20","article-title":"Analysis of influencing factors of chemotherapy-induced peripheral neurotoxicity","volume":"29","author":"Wang","year":"2017","journal-title":"Tianjin Pharm"},{"key":"B21","article-title":"Mechanisms and therapeutic advances in chemotherapy-induced neurotoxicity","volume":"21","author":"Ji","year":"2012","journal-title":"Chin J Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1005-9202.2020.14.015","article-title":"Clinical characteristics and influencing factors of peripheral neuropathy in elderly patients with diabetes","volume":"40","author":"Gao","year":"2020","journal-title":"Chin J Gerontology"},{"key":"B23","article-title":"Clinical observation of venlafaxine in the prevention of oxaliplatin-induced neurotoxicity","volume":"20","author":"Song","year":"2013","journal-title":"Chin J Cancer Prev Control"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx162","article-title":"Long-term peripheral neuropathy in breast cancer patients treated with adjuvant chemotherapy: NRG Oncology\/NSABP B-30","volume":"110","author":"Bandos","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-011-0352-x","article-title":"Paclitaxel-induced peripheral neuropathy in patients with breast cancer undergoing adjuvant chemotherapy","volume":"18","author":"Tanabe","year":"2013","journal-title":"Int J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx098","article-title":"Supplement use and chemo-induced peripheral neuropathy in a cooperative group trial (S0221): The DELCaP Study","volume":"109","author":"Zirpoli","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"B27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.5388\/aon.2019.19.2.71","article-title":"Factors influencing peripheral neuropathy of cancer patients undergoing chemotherapy","volume":"19","author":"Yoon","year":"2019","journal-title":"Asian Oncol Nurs"},{"key":"B28","article-title":"Analysis of chemotherapy-induced peripheral neuropathy and influencing factors in cancer patients","volume":"16","author":"Hong","year":"2019","journal-title":"Chin J Nurs Education"},{"key":"B29","volume-title":"Principles and practice of structural equation modeling","author":"Kline","year":"2015"},{"key":"B30","doi-asserted-by":"publisher","first-page":"150983","DOI":"10.1016\/j.soncn.2019.150983","article-title":"Proactive rehabilitation for chemotherapy-induced peripheral neuropathy","volume":"36","author":"Knoerl","year":"2020","journal-title":"Semin Oncol Nurs"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1177\/10547738221085613","article-title":"Severity, risk factors and quality of life of patients associated with chemotherapy-induced peripheral neuropathy","volume":"31","author":"Srivastava","year":"2022","journal-title":"Clin Nurs Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3870\/j.issn.1001-4152.2023.02.025","article-title":"Multi-mode exercise intervention in patients with chemotherapy-induced peripheral neuropathy","volume":"38","author":"Zha","year":"2019","journal-title":"J Nurs"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.3390\/cancers14051224","article-title":"Mechanisms, mediators, and moderators of the effects of exercise on chemotherapy-induced peripheral neuropathy","volume":"14","author":"Chung","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1327318\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T07:22:06Z","timestamp":1709796126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1327318\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":33,"alternative-id":["10.3389\/fonc.2024.1327318"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1327318","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,7]]},"article-number":"1327318"}}